Recurrent Papillary Craniopharyngioma with BRAF V600E Mutation Treated with Dabrafenib: A Case Report
Recurrent Papillary Craniopharyngioma with BRAF V600E Mutation Treated with Dabrafenib: A Case Report
复制标题
达拉非尼治疗伴 BRAF V600E 突变的复发性乳头状颅咽管瘤：一例病例报告
DOI：
--
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
J. Uhm
中科院分区：
文献类型：
--
作者：
B. Himes;M. Ruff;Jamie J. Van Gompel;Sean S. Park;E. Galanis;T. Kaufmann;J. Uhm
作者提出的情况下，一名男子乳头状颅咽管瘤，首次诊断在47岁，谁经历了多次复发。第一次切除的病理标本显示BRAF V600E突变。由于患者在52岁时进行手术和放疗后复发，因此决定开始使用BRAF V600E抑制剂dabrafenib治疗。开始使用dabrafenib后的影像学显示肿瘤大小减小。他继续接受达非尼治疗约1年，并继续显示出良好的临床结果。当时决定停止dabrafenib治疗，并进行连续影像学随访。自停用达非尼后1年多的随访，患者继续表现良好，无肿瘤进展的影像学证据，并继续通过频繁的间隔成像进行监测。
The authors present the case of a man with a papillary craniopharyngioma, first diagnosed at 47 years of age, who experienced multiple recurrences. Review of the pathologic specimen from his first resection demonstrated the BRAF V600E mutation. With his most recent recurrence following previous surgery and radiotherapy, at 52 years of age, the decision was made to initiate treatment with the BRAF V600E inhibitor dabrafenib. Imaging following initiation of dabrafenib demonstrated reduction in tumor size. He remained on dabrafenib therapy for approximately 1 year and continued to demonstrate a good clinical result. At that time the decision was made to discontinue dabrafenib therapy and follow up with serial imaging. After more than 1 year of follow-up since stopping dabrafenib, the patient has continued to do well with no radiographic evidence of tumor progression and continues to be monitored with frequent interval imaging.
影响因子：
4.1
作者：
Bunin, GR;Surawicz, TS;Bruner, JM
通讯作者：
Bruner, JM